Papers

2

Total Citations

32

H-Index

2

About

Dr. Mengchao Wei is a rising urologic surgeon and researcher whose work focuses on advancing minimally invasive surgical techniques for urologic cancers, particularly upper urinary tract urothelial carcinoma (UTUC) and renal tumors. His major contributions include two landmark comparative studies: a systematic review and meta-analysis of 24 citations that rigorously compared robot-assisted nephroureterectomy (RANU) with laparoscopic nephroureterectomy (LNU) for UTUC, providing critical evidence on whether robotic technology offers meaningful clinical advantages over standard laparoscopy. Additionally, Dr. Wei conducted a randomized controlled trial (8 citations) evaluating the AirSeal valve-less trocar insufflation system versus conventional insufflation in retroperitoneal robot-assisted laparoscopic partial nephrectomy—a pioneering study that addresses both clinical efficacy and cost-effectiveness in robotic urologic surgery. His work directly informs surgical decision-making by clarifying the benefits and trade-offs of emerging technologies. With a growing citation impact and a focus on high-quality comparative evidence, Dr. Wei is establishing himself as a key voice in the evolution of robotic urologic oncology, helping to define best practices for surgeons and improve outcomes for patients with complex urologic malignancies.

Research Focus

Key Achievements

2
H-Index
2
Papers
32
Total Citations
16
Avg Citations/Paper
🏆 Most Cited Paper
Robot-assisted vs. laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis based on comparative studies
24 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago